## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Anagnostou et al. Application No.: 09/525,808 Filing Date: March 15, 2000 Confirmation No. 9764 Group Art Unit: 1643

Examiner: Christopher H. Yaen

For: METHOD OF TREATING ENDOTHELIAL INJURY

January 21, 2009

Commissioner for Patents Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT COVER LETTER

Sir:

Attached is an Information Disclosure Statement listing of documents, together with a copy of any
listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S.
patent application publication is not provided herewith in accordance with 37 C.F.R. § 1.98(a)(2)(ii).
☐ In accordance with <b>37 CFR 1.97(b)</b> , the information disclosure statement is being filed:
$\square$ (1) within three months of the filing date of a national application other than a continued
prosecution application under §1.53(d);
$\square$ (2) within three months of the date of entry of the national stage as set forth in §1.491 in an
international application;
(3) before the mailing of a first Office Action on the merits; or
⋈ (4) before the mailing of a first Office Action after the filing of a request for continued
examination under §1.114.
☐ In accordance with <b>37 CFR 1.97(c)</b> , the information disclosure statement is being filed after the
period specified in 37 CFR 1.97(b) above, but before the mailing date of any of a final action under §1.113, a
notice of allowance under §1.311, or an action that otherwise closes prosecution in the application, and is
accompanied by one of the following:
(1) The statement specified under <b>37 CFR 1.97(e)</b> , as follows:
☐ Each item of information contained in the information disclosure statement was
first cited in any communication from a foreign patent office in a counterpart foreign
application not more than three months prior to the filing of the information disclosure
statement; <u>or</u>
No item of information contained in the information disclosure statement was
cited in a communication from a foreign patent office in a counterpart foreign application,
and, to the knowledge of the person signing the certification after making reasonable inquiry
no item of information contained in the information disclosure statement was known to any
individual designated in §1.56(c) more than three months prior to the filing of the information
disclosure statement; <u>or</u>
(2) The fee set forth in §1.17(p);

In re: Anagnostou et al. Application No.: 09/525,808 Filing Date: March 15, 2000 Page 2 of 2 In accordance with 37 CFR 1.97(d), the information disclosure statement is being filed after the period specified in 37 CFR 1.97(c) above, but on or before payment of the issue fee, and is accompanied by both of the following: (1) The statement specified under 37 CFR 1.97(e), as follows: ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement; and (2) The fee set forth in §1.17(p); In accordance with 37 CFR 1.97(g), the information disclosure statement shall not be construed as a representation that a search has been made. In accordance with 37 CFR 1.97(h), the information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56(b). ☐ The Director is hereby authorized to charge the fee specified in 37 C.F.R. § 1.17(p), and any fee deficiency or credit any overpayment, to Deposit Account No. 50-0220; or ☑ No fee is believed due. However, the Director is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220. Respectfully submitted.

> Shawna Cannon Lemon Registration No. 53,888 Attorney for Applicant(s)

**Customer Number 20792** 

Myers Bigel Sibley & Sajovec, P.A. P.O. Box 37428, Raleigh, NC 27627 919-854-1400 919-854-1401 (Fax)

Certificate of Mailing

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4) to the U,S Patent and Trademark Office on January 21, 2009.

Beffy-Llou Rosser